公开(公告)号：US09790274B2

公开(公告)日：2017-10-17

申请号：US14774795

申请日：2014-03-12

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Barrett R. Harvey ,  Kenneth L. Pinkston ,  Ali Azhdarina ,  Eva M. Sevick-Muraca

IPC: C07K16/00 ,  C07K16/28 ,  C07K16/30 ,  A61K47/48 ,  A61K51/10 ,  G01N33/574

CPC classification number: C07K16/28 ,  A61K47/6803 ,  A61K47/6865 ,  A61K51/1066 ,  A61K51/1093 ,  C07K16/30 ,  C07K16/3053 ,  C07K2317/33 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  G01N33/57434 ,  G01N2333/705

Abstract: Embodiments of the invention provide high affinity recombinant EpCAM-binding antibodies. Methods of using a such antibodies as imaging agents, diagnostics and therapeutics are also provided. Dual-nuclear and fluorescently labeled or singly fluorescently labeled contrast agents promise the advantage of molecularly-guided surgical resection via surgical field near-infrared fluorescence (NIRF) imaging following (in the case of dual labeled agents) nuclear imaging for general localization. Currently, nodal staging of most cancers is performed following lymph node (LN) biopsy and dissection for subsequent pathological examination.